Drug Search Results
More Filters [+]

Clivatuzumab tetraxetan

Alternative Names: clivatuzumab tetraxetan
Latest Update: 2020-12-07
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: MUC1 Binder

Novel Mechanism: Yes

Modality: Antibody

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Gilead Sciences
Company Location: FOSTER CITY CA 94404
Company CEO: Daniel P. O’Day
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Clivatuzumab tetraxetan

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Pancreatic Cancer|Adenocarcinoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

PANCRIT®-1

P3

Terminated

Pancreatic Cancer

2016-11-01

PANCRIT-1 (PANcreatic Cancer RadioImmunoTherapy Trial 1)

P3

Completed

Adenocarcinoma|Pancreatic Cancer

2016-03-14

Recent News Events

Date

Type

Title